MX2020002267A - Uso de cerebrolisina. - Google Patents
Uso de cerebrolisina.Info
- Publication number
- MX2020002267A MX2020002267A MX2020002267A MX2020002267A MX2020002267A MX 2020002267 A MX2020002267 A MX 2020002267A MX 2020002267 A MX2020002267 A MX 2020002267A MX 2020002267 A MX2020002267 A MX 2020002267A MX 2020002267 A MX2020002267 A MX 2020002267A
- Authority
- MX
- Mexico
- Prior art keywords
- cerebrolysin
- cadasil
- leukoencephalopathy
- patients
- disclosed
- Prior art date
Links
- 208000010482 CADASIL Diseases 0.000 abstract 2
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
| PCT/EP2018/073106 WO2019042983A1 (en) | 2017-08-28 | 2018-08-28 | USE OF CERBROLYSINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002267A true MX2020002267A (es) | 2020-10-22 |
Family
ID=59745228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002267A MX2020002267A (es) | 2017-08-28 | 2018-08-28 | Uso de cerebrolisina. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12589118B2 (enExample) |
| EP (2) | EP3449931B1 (enExample) |
| JP (1) | JP7281450B2 (enExample) |
| KR (1) | KR102676274B1 (enExample) |
| CN (1) | CN111050780B (enExample) |
| AU (1) | AU2018326339A1 (enExample) |
| CA (1) | CA3073991A1 (enExample) |
| EA (1) | EA202090108A1 (enExample) |
| ES (2) | ES2767070T3 (enExample) |
| HR (1) | HRP20200031T1 (enExample) |
| MX (1) | MX2020002267A (enExample) |
| PH (1) | PH12020500376A1 (enExample) |
| PL (2) | PL3449931T3 (enExample) |
| UA (1) | UA129400C2 (enExample) |
| WO (1) | WO2019042983A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198037A1 (en) * | 2019-03-25 | 2020-10-01 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| EP4114843B1 (en) | 2020-07-13 | 2023-08-16 | EVER Neuro Pharma GmbH | Method for producing a mammalian brain protein hydrolysate |
| KR20240159455A (ko) * | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE154608T1 (de) | 1990-04-12 | 1997-07-15 | Ebewe Arzneimittel | Verwendung einer mischung von peptiden and aminosäuren für die prophylaxis oder behandlung von dementia |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
-
2018
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en not_active Abandoned
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 UA UAA202001881A patent/UA129400C2/uk unknown
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 US US16/642,307 patent/US12589118B2/en active Active
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 KR KR1020207007069A patent/KR102676274B1/ko active Active
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en not_active Ceased
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019042983A1 (en) | 2019-03-07 |
| JP2020531568A (ja) | 2020-11-05 |
| US20200376040A1 (en) | 2020-12-03 |
| PH12020500376A1 (en) | 2020-12-07 |
| ES2901508T3 (es) | 2022-03-22 |
| CA3073991A1 (en) | 2019-03-07 |
| AU2018326339A1 (en) | 2020-03-05 |
| EP3449931A1 (en) | 2019-03-06 |
| EP3675879A1 (en) | 2020-07-08 |
| CN111050780A (zh) | 2020-04-21 |
| CN111050780B (zh) | 2023-11-03 |
| JP7281450B2 (ja) | 2023-05-25 |
| PL3449931T3 (pl) | 2020-06-01 |
| UA129400C2 (uk) | 2025-04-16 |
| KR102676274B1 (ko) | 2024-06-18 |
| EP3675879B1 (en) | 2021-09-15 |
| EA202090108A1 (ru) | 2020-03-31 |
| ES2767070T3 (es) | 2020-06-16 |
| HRP20200031T1 (hr) | 2020-03-20 |
| KR20200045503A (ko) | 2020-05-04 |
| PL3675879T3 (pl) | 2022-02-14 |
| US12589118B2 (en) | 2026-03-31 |
| EP3449931B1 (en) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273918A (en) | Trispecific proteins and methods of use | |
| IL267455A (en) | Phosphodiesterase inhibitors and methods of treating bacteria | |
| PH12020500376A1 (en) | Use of cerebrolysin | |
| SG11202002339XA (en) | Perfusion bioreactor and related methods of use | |
| IL261625B (en) | Inhibitors of menin-mll in bridged cycles and methods of use | |
| PH12015501370B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| TWD190312S (zh) | 項鍊 | |
| TWD178831S (zh) | 耳環 | |
| TWD178828S (zh) | 耳環 | |
| TWD177947S (zh) | 耳環 | |
| TWD176807S (zh) | 耳環 | |
| TWD175462S (zh) | 耳環 | |
| TWD177391S (zh) | 耳環 | |
| IL263230B (en) | Use of indazoles converted in position 2 for the treatment and prevention of autoimmune diseases | |
| TWD182273S (zh) | 耳環 | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| TWD187490S (zh) | 病患連接裝置 | |
| MX2016009858A (es) | Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso. | |
| IL263265A (en) | Use of mesenchymal stem cells and their parts | |
| EP3198004A4 (en) | TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE | |
| MX393780B (es) | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos | |
| TWD188417S (zh) | 手柄(一) | |
| GEP20217231B (en) | Methods for treatment and prophylaxis of hiv and aids | |
| IL270976A (en) | IL-8 inhibitors for use in the treatment and/or prevention of secondary bacterial infection | |
| PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |